Inflammatory Cytokine Signatures in Epilepsy: Distinguishing Drug-Resistant from Drug-Responsive Patients

A recent study adds to growing evidence that inflammation in the brain, known as neuroinflammation, may play an important role in epilepsy and in why some patients do not respond well to anti-seizure medications. Researchers focused on cytokines, small immune signaling proteins that help regulate inflammation and immune activity, to better understand their relationship to seizure severity and treatment resistance.

The study included 90 participants: 30 people with drug-resistant epilepsy (DRE), 30 with drug-responsive epilepsy (DREsp), and 30 healthy control participants. Researchers measured blood levels of five inflammatory cytokines — IL-1β, IL-6, IL-8, IL-17, and IL-18 — using laboratory testing methods designed to detect immune proteins in serum samples.

All five cytokines were significantly elevated in people with epilepsy compared to healthy controls, with the highest levels seen in patients with drug-resistant epilepsy. Among the markers studied, IL-6 and IL-8 were particularly effective at distinguishing people with epilepsy from healthy individuals, while IL-6 also showed a strong ability to differentiate drug-resistant epilepsy from drug-responsive epilepsy. IL-1β showed the strongest association with seizure frequency, with levels increasing progressively from healthy controls to drug-responsive epilepsy and then to drug-resistant epilepsy.

The researchers also found a stepwise increase in cytokine levels as seizure frequency increased, further supporting the connection between ongoing inflammation and more severe epilepsy. These findings strengthen the idea that immune system activity and chronic inflammation may contribute not only to the development of epilepsy, but also to treatment resistance in some patients.

The study suggests that inflammatory cytokines could eventually serve as biomarkers to help predict disease severity or treatment response. In the future, therapies that target inflammation and immune signaling pathways may offer new treatment options for people with drug-resistant epilepsy, particularly for patients who do not respond to standard anti-seizure medications.

Learn More